Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paroxetine response and adverse reactions by CYP2D6 metabolizer type in depressive and anxiety disorders
ChiCTR2000038462Phase 4Recruiting
- Sponsor
- Peking University Sixth Hospital
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paroxetine in major depressive disorder (MDD), generalized anxiety disorder (GAD) and panic disorder (3 cohorts), sponsored by Peking University Sixth Hospital. Primary endpoints: Hamilton Depression Rating Scale, Hamilton Anxiety Rating Scale and 1 more. Started Sep 2020; status: recruiting.
02
Drugs
paroxetine
03
Conditions
major depressive disorder (MDD)generalized anxiety disorder (GAD)panic disorder
Beyond the preview
Go deeper on ChiCTR2000038462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038462.